FOXO4-DRI: The Peptide That Tells Worn-Out Cells to Finish the Job
Some cells stop dividing but refuse to die, lingering and causing trouble. This compound is designed to remove the excuse they are using.
What Is FOXO4-DRI?
FOXO4-DRI is a designed peptide aimed at senescent cells — cells that have stopped dividing but have not cleared out. It works by disrupting an interaction between two proteins, FOXO4 and p53, that keeps such cells alive.
Senescent cells, in plain language: imagine an employee who stopped working years ago but still occupies a desk, draws power, and spends the day complaining loudly enough to disrupt everyone around them. That is a senescent cell. It no longer divides or does its job, but it has not left — and worse, it emits inflammatory signals that degrade the tissue around it. The body normally clears these cells; with age, clearance falls behind and they accumulate. A senolytic is not a stimulant or a repair signal. It is a redundancy notice.
What the Research Examines
The mechanism is specific. Senescent cells survive partly because FOXO4 binds p53 — the protein that would otherwise trigger cell death — and holds it away from where it would act. FOXO4-DRI is built to disrupt that binding, releasing p53 and allowing the cell to complete the process it had stalled.
The "DRI" refers to retro-inverso design: the sequence is reversed and built from mirror-image amino acids, a technique used to make a peptide far more resistant to breakdown. Published work is preclinical, chiefly the 2017 Baar study in mice reporting restored fitness, fur density and kidney function in aged animals. No human trials have established these findings, and there is no regulatory approval.
Frequently Asked Questions
Compiled by the Southern Pacific Labs research team. Last updated July 2026.
Published References
- Baar MP, Brandt RMC, Putavet DA, et al. “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.” Cell, 2017. PubMed
- van Deursen JM. “The role of senescent cells in ageing.” Nature, 2014. PubMed
- Kirkland JL, Tchkonia T. “Senolytic drugs: from discovery to translation.” Journal of internal medicine, 2020. PubMed
- Childs BG, Gluscevic M, Baker DJ, et al. “Senescent cells: an emerging target for diseases of ageing.” Nature reviews. Drug discovery, 2017. PubMed
Related Research Guides
More in Bioregulators & Neuropeptides
A different approach to cellular ageing — telomere maintenance rather than cell clearance.
Read guide →Essential ReadingTissue-specific maintenance signals, a contrasting strategy.
Read guide →Mitochondrial-TargetedMitochondrial maintenance as another angle on cellular ageing.
Read guide →